Cyclosporine In Takotsubo Syndrome

Summary

The goal of this clinical trial is to investigate the impact of repetitive acute Cyclosporine A (CsA) bolus therapy in patients suffering from TTS with an elevated risk of impaired outcome. The main question it aims to answer is whether CsA reduces myocardial injury (primary outcome). Participants will receive CsA or placebo at baseline and every 12h in the first 24h after study inclusion. Researchers will compare CsA and the placebo group to see if a) myocardial injury is reduced, and b) ejection fraction is improved compared to baseline, as well as several other secondary endpoints over a one year follow-up.

Timeline

Start

2025-02-01

Primary completion

2027-02

Completion

2028-02

Publications

• Bruns B, Elsous N, Burghaus I, Steyrer K, Joos M, Kramer T, Scheffel M, Blankenberg S, Eitel I, Massberg S, Thiele H, Meder B, Backs J, Frey N. Rationale and design of the cyclosporine in Takotsubo syndrome (CIT) trial. Am Heart J. 2025 Nov;289:147-157. doi: 10.1016/j.ahj.2025.04.020. Epub 2025 Apr 21.

Drugs

Indications